About Us

Emisphere Technologies is a Drug Delivery Company whose core business strategy is to partner its proprietary drug delivery technology and license Eligen B12.  Our thirty year history has made us the established leader in converting injectable therapeutics into advanced oral formulations. Utilizing our experience in researching, developing and manufacturing a number of fully characterized carriers in our extensive library, our partners leverage our expertise to employ our unique intracellular delivery mechanism to advance their portfolio and create differentiated line extensions.  Our capabilities range from early proof of concept, to extensive development and commercial capabilities.

Emisphere’s technology can enhance the clinical profile of both pre-market and currently marketed products.  Further, our broad-based proprietary oral drug delivery platform provides significant increases in bioavailability, facilitates the enhanced absorption of small and large molecules without altering their chemical form, and maintains their biological integrity or pharmacological properties.  Finally, it is especially useful for oral delivery of peptides, proteins, oligonucleotides and oligosaccharides.

Potential Application of the Eligen® Technology

We believe that the Eligen® drug delivery technology is well suited to facilitate the safe and effective oral absorption of emerging peptides and biologics products that are typically only available as injectibles or are currently under development. We believe that these products represent tremendous promise for realizing improvements in healthcare and growth in the industry. In the cases that such molecules are delivered by injection due to limited benefits, our technology may increase the benefit of the therapy by improving bioavailability, absorption or by decreasing time to onset of action.

  • In the cases that such molecules are delivered by injection due to limited benefits, our technology may increase the benefit of the therapy by improving bioavailability, absorption or by decreasing time to onset of action.
  • The Eligen® Technology can make it possible to deliver certain therapeutic molecules orally without altering their chemical form or biological activity.
  • The Eligen® Technology can be applied to other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal or transdermal.
  • Eligen® “carriers”, enable the transport of therapeutic molecules across the mucous membranes of the gastrointestinal tract, to reach the tissues of the body where they can exert their intended pharmacological effect.
  • Our development efforts are conducted internally or in collaboration with corporate development partners.
  • Typically, the drugs that we target are at an advanced stage of development, or have already received regulatory approval, and are currently available on the market.

Executive Management Team

Alan L. Rubino

Chief Executive Officer
View Biography

Carl V. Sailer

Vice President of Sales & Marketing
View Biography

M. Gary I. Riley, DVM. Ph.D., DACVP.DABT

Chief Scientific Officer
View Biography

Nicholas G. Rothwell, CPIM

Vice President, Global Supply
View Biography

David Gschneidner Ph.D.

Vice President, Carrier R&D
View Biography

Carlos de Lecea, M.D.

Global Head of Business Development
View Biography

Board of Directors

John D. Harkey Jr.

Director
View Biography

Tim McInerney

Director
View Biography

Jacob M. Plotsker

Director
View Biography

Mark H. Rachesky, M.D.

Director
View Biography

Timothy G. Rothwell

Chairman
View Biography

Alan L. Rubino

Chief Executive Officer and President
View Biography

Michael Weiser, M.D., Ph.D.

Director
View Biography